|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AbbVie, AstraZeneca, Beigene, and Pharmacyclics LLC,
an AbbVie Company and Janssen Biotech, Inc.
Description:
Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone
marrow that affects older adults. CLL is the most common type of
leukemia in adults. It affects B cell lymphocytes, which originate
in the bone marrow, develop in the lymph nodes, and normally fight
infection by producing antibodies. In 2022, it is expected that
there were 20,160 new cases of CLL and about 4,410 deaths, which
represents an increase in both numbers. Patients with CLL are often
diagnosed when they are asymptomatic; therefore, knowing when to
initiate treatment may pose a challenge to clinicians. Furthermore,
patients with CLL have impaired immune systems and multiple
comorbidities, which can complicate management and impact treatment
decisions. Fortunately for patients with CLL, several new
treatments, including BTK inhibitors, have recently become available
giving clinicians many new options to improve patient outcomes with
these new treatments and strategies. This activity focuses on these
evolving treatments and strategies, outlines how to incorporate
quality measures for the diagnosis and management of CLL, and
describes how to apply evidence-based data to select appropriate
treatment regimens and manage toxicities. With the availability of
new treatments, it is critical that medical directors, oncologists,
nurses and other healthcare professionals are updated on these
emerging options, guidelines and strategies for implementing them
into the treatment paradigm, which will ultimately improve patient
outcomes.
Upon completion of this
activity, participants will be able to:
-
Discuss the clinical and economic
burden of chronic lymphocytic leukemia (CLL) in terms of
relative survival, mortality, drug utilization, adverse event
management, and hospitalizations
-
Examine relevant prognostic factors
in CLL and assess the importance of molecular testing to guide
clinical decision making and treatment selection
-
Evaluate current evidence from
pivotal clinical trials, head-to-head comparisons, and practice
guidelines on BTK inhibitor efficacy, safety, and
mechanistic/selectivity differences, including as single-agent
approaches or as part of novel combinations with BCL-2
inhibitors
-
Identify patients with CLL for whom
a BTK inhibitor is an appropriate choice in the management of
their cancer
-
Differentiate the safety profiles
for BTK inhibitors and their combinations as well as monitoring
and management strategies to mitigate adverse effects
-
Analyze the cost drivers associated
with CLL and the potential impact of novel combination therapies
to improve patient outcomes and healthcare utilization
|
Faculty: |
Javier Pinilla Ibarz,
MD, PhD
Senior Member, Head of the Lymphoma Section
Director of Immunotherapy
Malignant Hematology Department
Moffitt Cancer Center |
|
Disclosure:
|
(Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Pinilla Ibarz has served as a consultant for AbbVie,
AstraZeneca, BeiGene, BMS, Janssen, Lilly, Novartis,
Pfizer, Takeda, and Sanofi. He has served as a speaker
for AbbVie, AstraZeneca, BeiGene, Genentech, Janssen,
Pfizer, and Takeda. His presentation has been reviewed
for any bias.
|
|
Planning Committee: |
Bill
Williams, MD has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jeremy Williams has no relevant financial relationships
with an ineligible company in the last 24 months to
disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships with an ineligible company in the last 24
months to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity. |
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
This activity is supported by educational grants from
AbbVie, AstraZeneca, Beigene, and Pharmacyclics LLC,
an AbbVie Company and Janssen Biotech, Inc.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |